Lund

BESS POWER CORPORATION REACHES ITS FIRST MILESTONE: ERCOT CONFIRMS THE CAPACITY OF LUND STORAGE PROJECT FOR A TOTAL POWER OF 407.55 MW

Retrieved on: 
Monday, July 3, 2023
ERCOT, FIS, Electric Reliability Council of Texas, Lund, Lower Colorado River Authority, SPV, Renewable energy

Lund Storage has an import/export capacity of 407.55 MW, establishing it as one of the largest utility-scale energy storage projects in the state of Texas.

Key Points: 
  • Lund Storage has an import/export capacity of 407.55 MW, establishing it as one of the largest utility-scale energy storage projects in the state of Texas.
  • BESS Power Corp, is owned jointly by Redelfi, a Euronext Milan listed company, Altea Green Power, and the U.S. based developer Elio Energy Group LLC.
  • BESS Power purchased the US-registered SPV Lund Storage Center 1 LLC earlier this year, which is located on 50 acres of privately-owned land in Travis County, Texas.
  • Lund Storage is now moving forward with the Full Interconnect Study, with a projected commercial operations date in 2026.

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2021

Retrieved on: 
Tuesday, March 1, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Investor, Executive, Neuro, Diagnosis, Deloitte, Achievement, News, PET, Board, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Webcast, FY, Eli Lilly, Roman Hrusovsky, Neurodegeneration, Telecommunication, RUO, NASDAQ, AFL, Biogen, University, Lists of diseases, PerkinElmer, Industry, Company, Lund University, Antibody, EMERGE, Pathology, Disease, Pfizer, Food, Data, Eli Lilly and Company, Emergency Use Authorization, Science, EUA, FDA, Lilly, AD, Blood, AAIC, EST, Patient, Conference, Baozou Big News Events, Nature Communications, Publication, Corporation, CEO, GAAP, Lund, Plasma, Dementia, Pharmaceutical industry, Management, Self storage, Medical device, Medical imaging

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending December 31, 2021.
  • Quanterix had $399.0 million in cash, cash equivalents and restricted cash on the balance sheet as of December 31, 2021.
  • Quanterix Simoa technology was highlighted in a record 465 new publications in 2021, bringing total Simoa-specific inclusions to over 1,585.
  • In conjunction with this announcement, Quanterix Corporation will host a conference call on March 1, 2022 at 8:30 a.m. EST.

Quanterix Provides Operational and Preliminary Financial Highlights

Retrieved on: 
Thursday, January 13, 2022
Research, Pharmaceutical, Oncology, Technology, Infectious Diseases, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Other Technology, Health, Other Science, Research, Neurodegeneration, Private Securities Litigation Reform Act, Donanemab, Science, NASDAQ, Plasma, Neuro, Emergency Use Authorization, BBC, Efficiency, Diagnosis, Lilly, Telecommunication, Technology, Tau, Dementia, Conference, Publication, PET, Abbott, COVID-19, Risk, Eli Lilly, Infection, Company, Deloitte, Corporation, FDA, CCO, Lund, U.S. Securities and Exchange Commission, Forward-looking statement, Patient, News, Inflammation, Cardiology, Viral Research and Diagnostic Laboratories, Solution, EST, Roman Hrusovsky, Review, PST, Lund University, Biogen, Longevity, Antibody, Population, Quality of life, Pathology, Data, EMERGE, Neurology, Omicron, University, Interview, Pharmaceutical industry, Medical device, Medical imaging, Management

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.
  • Quanterix pTau-181 assay was granted Breakthrough Device Designation from the U.S. FDA as an aid in the diagnosis of Alzheimers disease.
  • Quanterix Simoa technology was highlighted in a record 465 new publications in 2021, bringing total Simoa-specific inclusions to over 1,585.
  • Hired President and CCO in 2021 to accelerate the operational scaling of Quanterix RUO opportunity and to catalyze the symbiotic relationship between Research and Diagnostic.

Active Biotech's nomination committee appointed

Retrieved on: 
Friday, December 10, 2021
Naptumomab estafenatox, Patient, Laquinimod, Annual general meeting, CEO, Committee, NASDAQ, Biotechnology, Multiple myeloma, ACTI, AGM, Therapy, CFO, Lymphatic system, Board, Partnership, Annual, CET, Motor vehicle, Pharmaceutical industry

If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.

Key Points: 
  • If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.
  • Based on the above, the Nomination Committee is composed with participants representing the largest shareholders in Active Biotech as of September 30, 2021, and consists of:
    For the 2022 Annual General Meeting, the Nomination Committee shall prepare and submit proposals regarding the Chairman of the AGM, the number of Board members, a Chairman and Board members elected by the AGM, the fees and other renumerations to Board members and Board committees, number of auditors, the auditor, fees to auditors and election of a Nomination Committee.
  • Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership.
  • Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors.

First subject dosed in phase I clinical study with eye-drop formulation of laquinimod  

Retrieved on: 
Friday, December 10, 2021
Severe cognitive impairment, Risk, Eye, Retina, Naptumomab estafenatox, Review, Ciliary body, Tissue, Uvea, Biotechnology, Steroid, Body, Pharmacokinetics, Choroid, Multiple sclerosis, Inflammation, Oxygen, Safety, Patient, Phenotype, Therapy, Optic nerve, Lymphatic system, CEO, Partnership, Laquinimod, ACTI, EU, MS, Uveitis, Multiple myeloma, Trial of the century, CFO, NASDAQ, Nutrient, Iris, III, Pharmaceutical industry

Lund, December 10, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the companys candidate drug laquinimod.

Key Points: 
  • Lund, December 10, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first subject has been dosed in the phase I clinical study of the newly developed eye-drop formulation of the companys candidate drug laquinimod.
  • A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.
  • The primary endpoint of the study is to determine the safety and tolerability of laquinimod eye-drops after single and repeat doses.
  • Laquinimod is advancing to a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis.

Brunswick Corporation announces major capacity expansion of Reynosa manufacturing facility – will increase production capability by 60 percent

Retrieved on: 
Wednesday, December 8, 2021
ASG, Freedom Boat Club, NYSE, Ginga Sengoku Gun'yūden Rai, Electronics, Income, Environment, Company, Atwood (surname), Risk, Forward-looking statement, GLOBE, Climate change, Growth, Leadership, Private Securities Litigation Reform Act, Coronavirus, Brunswick Corporation, Bayliner, News, Â, Walmart, Lowe, BLA, Lund, Transport, Policy, Oil, COVID-19, Brunswick Boat Group, Asia Venture Group, Intellectual property, Acquisition, Compliance, Mercury Marine, Marine, Mercury, Risk management

The expansion will increase production capability by close to 60 percent.

Key Points: 
  • The expansion will increase production capability by close to 60 percent.
  • The expansion will create more than 600 jobs in the local economy.
  • This is the fourth major expansion for the Brunswick Boat Group in 2021 and is consistent with the Companys announced plans to increase capacity efficiently and cost-effectively.
  • Additionally, the Company made a recent acquisition near its New York Mills facility in Minnesota to increase production capacity and vertical integration.

Terranet Unveils BlincBike, Cutting-edge Micromobility Safety Tech

Retrieved on: 
Monday, December 6, 2021
Algorithm, Insurance, Safety, Movement, Technology, Time, Attention, Fatality, Heel, Eye, TerraNet AB, Machine learning, Nasdaq, TerraNet, Smartphone, Build automation, ADAS, Intention, Accident, Rear-view mirror, Road, Television

Terranet, the creators of groundbreaking vehicle safety technology, VoxelFlow announced today their latest e-bike innovation for urban mobility, BlincBike, a landmark step forward for micromobility safety.

Key Points: 
  • Terranet, the creators of groundbreaking vehicle safety technology, VoxelFlow announced today their latest e-bike innovation for urban mobility, BlincBike, a landmark step forward for micromobility safety.
  • The first of its kind safety product will help bicyclists keep their eyes on the road ahead and fits into any e-bike.
  • BlincBike is our first product to target micromobility, but we see a tremendous potential in providing safety products in the forsaken and rapidly expanding micromobility space, said Terranet CTO Nihat Kk.
  • With a vision to save lives Terranet designs and develops a new class for vision-based sensor systems, used for road safety.

Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021

Retrieved on: 
Tuesday, November 30, 2021
Patient, CEO, Naptumomab estafenatox, Partnership, Cancer, Multiple myeloma, Laquinimod, Walter, Annual general meeting, Society, CET, Neoplasm, ACTI, Communication, CFO, NASDAQ, Biotechnology, TTS, Washington Convention Center, Poster, Therapy, SITC, Immunotherapy, Walter E. Washington Convention Center, Lymphatic system, Vaccine, Pharmaceutical industry

The presented data shows that naptumomab generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro.

Key Points: 
  • The presented data shows that naptumomab generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro.
  • NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform.
  • Naptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016.
  • NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.

Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Tuesday, November 9, 2021
SITC, Lymphatic system, Cancer, ACTI, NAP, Therapy, Neoplasm, NASDAQ, EST, CEO, Date-time group, Society, Laquinimod, Naptumomab estafenatox, Partnership, Multiple myeloma, Society for Immunotherapy of Cancer, Biotechnology, Annual general meeting, Central European Time, CET, Walter, Immunotherapy, Communication, TTS, Patient, CFO, EU, Pharmaceutical industry

The poster presentation will highlight preclinical data demonstrating that naptumomab enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.

Key Points: 
  • The poster presentation will highlight preclinical data demonstrating that naptumomab enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.
  • NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform.
  • NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.
  • This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation.

Terranet Unveils State of the Art Showroom in Stuttgart

Retrieved on: 
Tuesday, November 9, 2021
Well, Safety, Industry, Audi, TerraNet AB, Heart, Eye, Technology, ADAS, CTO, Company, Death, Time, Walking, Nasdaq, Mercedes-Benz, Weather, Car dealership

As Terranets first private demo space, the showroom represents a new era of expansion for the rapidly growing tech company.

Key Points: 
  • As Terranets first private demo space, the showroom represents a new era of expansion for the rapidly growing tech company.
  • Terranets presence in Stuttgart marks a significant step in cementing the Company as an international industry leader in the automotive safety space.
  • We are thrilled to continue expanding our European presence and partnering with other international heavyweights in the industry, said Nihat Kk, CTO at Terranet.
  • Within walking distance of Terranet partner Mercedes-Benz, the new location will place Terranet in the heart of the city and the automotive capital of Europe.